Jung Jae Ik, Cho Hee Kyung
Department of Rehabilitation Medicine, Daegu Catholic University School of Medicine, Korea.
J Yeungnam Med Sci. 2025;42:23. doi: 10.12701/jyms.2025.42.23. Epub 2025 Jan 21.
The coronavirus disease 2019 (COVID-19) pandemic prompted the development of messenger RNA vaccines. Following extensive vaccination campaigns worldwide, several adverse reactions to these vaccines have been reported. This is a case series of unilateral lower extremity lymphedema after COVID-19 vaccination in two patients with a history of cervical cancer. An 82-year-old woman and a 68-year-old woman visited the outpatient clinic with unilateral leg edema after receiving a COVID-19 booster vaccine (BNT162b2; Pfizer-BioNTech) in the deltoid muscle. Both patients had a common history of cervical cancer treated with surgery, chemotherapy, and radiotherapy and were in complete remission. Gynecological evaluations, including laboratory and imaging studies, revealed no specific findings. Lymphoscintigraphy revealed delayed lymphatic drainage with diffuse dermal backflow in a unilateral lower extremity. This case series explores adverse reactions to COVID-19 vaccination in patients who are at high risk of developing lymphedema, providing novel data for similar clinical presentations.
2019年冠状病毒病(COVID-19)大流行促使信使核糖核酸疫苗的研发。在全球范围内广泛开展疫苗接种运动后,已报告了这些疫苗的几种不良反应。本文是一系列关于两名有宫颈癌病史的患者在接种COVID-19疫苗后出现单侧下肢淋巴水肿的病例。一名82岁女性和一名68岁女性在三角肌接种COVID-19加强疫苗(BNT162b2;辉瑞-生物科技公司)后因单侧腿部水肿前来门诊就诊。两名患者均有宫颈癌手术、化疗和放疗史且处于完全缓解状态。包括实验室和影像学检查在内的妇科评估未发现特异性结果。淋巴闪烁造影显示单侧下肢淋巴引流延迟伴弥漫性真皮反流。该病例系列探讨了有发生淋巴水肿高风险患者对COVID-19疫苗接种的不良反应,为类似临床表现提供了新的数据。